[Recommendations for the treatment of premature ejaculation].
Recommandations pour le traitement de l’éjaculation prématurée.
Dapoxetine
Dapoxétine
Médecine sexuelle
Premature ejaculation
Sexologie
Sexology
Sexual medicine
Éjaculation précoce
Journal
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie
ISSN: 1166-7087
Titre abrégé: Prog Urol
Pays: France
ID NLM: 9307844
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
04
01
2023
accepted:
10
02
2023
medline:
4
4
2023
pubmed:
4
3
2023
entrez:
3
3
2023
Statut:
ppublish
Résumé
The Post-University Interdisciplinary Association of Sexology (AIUS) has brought together a panel of experts to develop French recommendations for the management of premature ejaculation. Systematic review of the literature between 01/1995 and 02/2022. Use of the clinical practice guidelines (CPR) method. We recommend giving all patients with PE psychosexological counseling, and whenever possible combining pharmacotherapies and sexually-focused cognitive-behavioral therapies, involving the partner in the treatment process. Other sexological approaches could be useful. We recommend the use of dapoxetine as first-line, on-demand oral therapy for primary and acquired PE. We recommend the use of lidocaine 150mg/mL/prilocaine 50mg/mL spray as local treatment for primary PE. We suggest the combination of dapoxetine and lidocaine/prilocaine in patients insufficiently improved by monotherapy. In patients who have not responded to treatments with marketing authorisation, we suggest using an off-label SSRI, preferably paroxetine, in the absence of a contraindication. We recommend treating ED before PE in patients with both symptoms. We do not recommend using α-1 blockers or tramadol in patients with PE. We do not recommend routine posthectomy or penile frenulum surgery for PE. These recommendations should contribute to improving the management of PE.
Identifiants
pubmed: 36868935
pii: S1166-7087(23)00045-3
doi: 10.1016/j.purol.2023.02.003
pii:
doi:
Substances chimiques
dapoxetine
GB2433A4M3
Benzylamines
0
Lidocaine, Prilocaine Drug Combination
0
Types de publication
Review
English Abstract
Practice Guideline
Langues
fre
Sous-ensembles de citation
IM
Pagination
237-246Informations de copyright
Copyright © 2023 Elsevier Masson SAS. All rights reserved.